Compare Meta Platforms Inc (META) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Neurocrine Biosciences Inc — how do they compare? Meta Platforms Inc trades at $599.55 (market cap $1.52T), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Meta Platforms Inc is far larger — about 90.7× Neurocrine Biosciences Inc's market cap, and Meta Platforms Inc pays a 0.35% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| META | NBIX | |
|---|---|---|
Market Cap | $1.52T | $16.76B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $185.50 |
52-Week Low | $525.72 | $123.10 |
Enterprise Value | $1.54T | $16.78B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META stock trades at $594.92, up 0.48% over 24 hours, with a bearish technical signal driven by moving averages and overbought short-term RSI. The company reported strong Q1 2026 earnings of $10.44 EPS, beating expectations, but missed in Q2 2026. Revenue growth remains robust, with 2025 revenue at $200.97 billion, though net income dipped to $60.46 billion. Recent news highlights the launch of AI model Muse Spark and a legal ruling in Massachusetts over youth addiction claims.
Outlook is mixed: analyst consensus is bullish with a $761.95 price target, citing AI innovations and solid fundamentals, but risks include high capital expenditure, regulatory lawsuits, and competitive pressures. The stock's valuation metrics like P/E of 22.41 suggest room for growth if execution continues, but investors should weigh legal and market volatility concerns.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
